{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.41","upperLimit":"20.34","value":"13.70"},{"groupId":"OG001","lowerLimit":"19.15","upperLimit":"33.41","value":"22.93"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"353"}],"units":"Participants"}],"description":"The time between the date of randomization and the date of first documented recurrence (local non-urothelial tract or distant), or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo","id":"OG000","title":"Placebo"},{"description":"Nivolumab 240mg IV Q2W","id":"OG001","title":"Nivolumab"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants","reportingStatus":"POSTED","timeFrame":"up to 53 months","title":"Non-Urothelial Tract Recurrence Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}